



(WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPX₁YYGX₂SHWYFDV, wherein X₁ is Y or H and X₂ is S or T; SEQ ID NO: 129).

48. (New) The method of claim 47, said humanized anti-VEGF antibody comprising the amino acid sequence of SEQ ID NO:7.

49. (New) The method of claim 47, said humanized anti-VEGF antibody having a heavy chain variable domain comprising the following hypervariable region amino acid sequences: CDRH1 (GYTFTNYGMN; SEQ ID NO:1), CDRH2 (WINTYTGEPTYAADFKR; SEQ ID NO:2) and CDRH3 (YPHYYGSSHWYFDV; SEQ ID NO:3).

50. (New) The method of claim 43, said humanized anti-VEGF antibody having a light chain variable domain comprising the following hypervariable region amino acid sequences: CDRL1 (SASQDISNYLN; SEQ ID NO:4), CDRL2 (FTSSLHS; SEQ ID NO:5) and CDRL3 (QQYSTVPWT; SEQ ID NO:6).

51. (New) The method of claim 50, said humanized anti-VEGF antibody comprising the amino acid sequence of SEQ ID NO:8.

52. (New) The method of claim 43, said humanized anti-VEGF antibody having a heavy chain variable domain comprising the amino acid sequence of SEQ ID NO:7 and a light chain variable domain comprising the amino acid sequence of SEQ ID NO:8.

53. (New) The method of claim 43, wherein said humanized anti-VEGF antibody is a full length antibody.

54. (New) The method of claim 53, wherein said humanized anti-VEGF antibody is a human IgG.

55. (New) The method of claim 43, wherein said humanized anti-VEGF antibody is an antibody fragment.

56. (New) The method of claim 55, wherein said humanized anti-VEGF antibody is a Fab.

57. (New) The method of claim 43, wherein said subject has a retinal disease.

58. (New) The method of claim 57, wherein said retinal disease is age-related macular degeneration (AMD).

59. (New) The method of claim 58, wherein the humanized anti-VEGF antibody is administered to the subject at a dose of at least about 0.5mg/kg.